Table 5.
Review and comparison of bacterial endophthalmitis isolates.
| UPMC19 | NYEEI13 | BPEI15 | Toronto18 | Hyderabad17 | Hyderabad14 | Queensland16 | CGMH* | |
|---|---|---|---|---|---|---|---|---|
| USA | USA | USA | Canada | India | India | Australia | Taiwan | |
| Study period | 1993–2015 | 1987–2011 | 2002–2011 | 2000–2009 | 1991–2015 | 2010–2013 | 1998–2013 | 1996–2019 |
| No. of isolates | 665 | 943 | 375 | 265 | 2840 | 196 | 193 | 901 |
| Gram-positive isolates | 92.9% | 89.2% | 87.2% | 90.2% | 68.7% | 37.2% | 84.5% | 49.9% |
| Susceptibility to vancomycin | 99.7% | 99.7% | 100.0% | 99.6% | 96% | 100.0% | 100.0% | 99.8% |
| Gram-negative isolates | 7.1% | 10.8% | 12.8% | 9.8% | 32.3% | 62.8% | 15.5% | 49.6% |
| Susceptibility to amikacin | 95.7% | 92.9% | N/A | N/A | 64–67%a | 87.0% | 100.0% | 93.7% |
| Susceptibility to ceftazidime | 93.6% | 91.5% | 100.0% | 100.0% | 69–38%a | 82.0% | 100.0% | 96.9% |
BPEI Bascom Palmer Eye Institute, CGMH Chang Gung Memorial Hospital, N/A not available, NYEEI New York Eye and Ear Infirmary, UPMC University of Pittsburgh Medical Center.
*Including 4 Gram-variable isolates.
a2005 → 2015.